Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions
MWN-AI** Summary
Paysign, Inc. (NASDAQ: PAYS) has announced significant results from its 2025 performance analysis of patient affordability solutions. The company is a prominent provider of various financial programs within the life sciences sector, including pharmaceutical copay programs. In 2025, Paysign expanded its offerings by adding 55 new programs, culminating in a total of 131 active programs. Notably, the company’s Dynamic Business Rules technology played a crucial role in these advancements, allowing for the identification of claims affected by copay maximizers with an impressive 97% accuracy.
In 2025, Paysign's innovative solutions saved pharmaceutical sponsors over $325 million, marking a more than 200% increase compared to the previous year. The company supported 131 retail and specialty pharmaceutical programs across various therapeutic categories, serving over 840,000 unique patients. Overall, Paysign facilitated more than $950 million aimed at prescription fulfillment expenses.
Matt Turner, President of Patient Affordability at Paysign, heralded 2025 as an outstanding year, emphasizing the importance of addressing the evolving financial threats faced by clients and patients. CEO Mark Newcomer also highlighted the company’s ongoing commitment to innovation in the healthcare sector, aiming to enhance solutions that support their partners and patients.
Paysign’s patient affordability platform offers customizable tools designed to address the specific needs of copay assistance programs, enabling real-time adjustments to program criteria. This cutting-edge approach is aimed at mitigating the adverse effects of copay accumulators and maximizers. Overall, 2025 has solidified Paysign's position in the healthcare ecosystem, showcasing its capacity to deliver substantial value to patients and pharmaceutical sponsors alike.
MWN-AI** Analysis
In light of Paysign, Inc.'s (NASDAQ: PAYS) recent performance analysis for 2025, investors should assess the company's strategic advancements and market positioning in the patient affordability sector. The addition of 55 new pharmaceutical copay programs and an impressive total of 131 programs demonstrates Paysign's growing influence in the healthcare and life sciences industries, positioning the company favorably amidst rising financial pressures faced by patients and pharmaceutical sponsors.
The company’s proprietary Dynamic Business Rules technology, which achieved a 97% accuracy rate in identifying claims subject to copay maximizers, has proven essential in saving clients over $325 million—an increase of more than 200% from the previous year. This substantial cost-saving achievement not only enhances Paysign's value proposition but also reflects its commitment to addressing the financial barriers to healthcare.
As the market for patient affordability solutions expands, Paysign's focus on real-time modifications to program criteria could set it apart from competitors. With healthcare costs expected to rise, the demand for effective copay assistance programs is likely to increase. Paysign's capability to adapt its offerings to meet the needs of various therapeutic classes and pharmaceutical manufacturers enhances its competitive advantage.
Investor sentiment may also be buoyed by the company's clear trajectory of growth, as evidenced by its support of over 840,000 unique patients and its facilitation of nearly $950 million in prescription fulfillment expenses in 2025. Looking ahead, the imperative of mitigating costs for healthcare manufacturers while ensuring patient access presents ongoing opportunities for Paysign.
Given these encouraging indicators, investors may want to consider adding Paysign to their portfolios as it continues to evolve in a crucial segment of the fintech and healthcare intersection. Continuous innovation and operational scalability remain paramount for the company to maintain its growth momentum into 2026 and beyond. However, potential investors should remain aware of the inherent risks associated with the healthcare sector indicated in Paysign's forward-looking statements.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Dynamic Business Rules Demonstrates the Company’s Advanced Capabilities in Mitigating Copay Maximizers, Exiting 2025 With 131 Active Programs
Paysign, Inc. (NASDAQ: PAYS ), a leading provider of patient affordability programs, donor compensation solutions and integrated payment processing for the life sciences industries, today announced its annual performance analysis of pharmaceutical copay programs. The company added 55 programs during 2025, exiting the year with 131 programs – many incorporating Paysign’s Dynamic Business Rules feature, which saved pharmaceutical clients more than $325 million by mitigating the harmful financial impact of copay maximizers on patients and program sponsors.
Dynamic Business Rules identifies impacted claims on the first prescription fill with 97 percent accuracy – an industry first and unique capability that has established the technology as a cornerstone of Paysign’s patient affordability business.
Paysign’s innovative patient affordability solutions achieved these results in 2025:
- Saved more than $325 million for pharmaceutical program sponsors by preventing funds diversion, an increase of more than 200% from 2024
- Supported 131 retail and specialty pharmaceutical programs across diverse therapeutic classes, greater than 70% increase from 2024
- Assisted more than 840,000 unique patients
- Assisted pharmaceutical clients in delivering more than $950 million toward prescription fulfillment expenses
“2025 was an outstanding year for this business,” said Matt Turner, President of Patient Affordability at Paysign. “New financial threats emerge annually for our clients and their patients. Our continued focus on these challenges delivers lasting value for our clients and ensures patients maintain access to critical therapies. As we enter 2026, we are more driven than ever to identify and mitigate program risks that increase costs for pharmaceutical manufacturers by providing lifesaving patient affordability solutions designed to reduce the cost of healthcare in America.”
The 2025 results demonstrate Paysign’s expanding presence across the healthcare ecosystem. Substantial growth in patient and client savings highlights the advanced efficacy of the company’s solutions and underscores its ability to deliver greater value to patients and pharmaceutical program sponsors.
“Reaching these significant milestones reflects the innovative drive at the heart of our patient affordability solutions,” said Mark Newcomer, Chief Executive Officer of Paysign. “Paysign continues to grow within healthcare and life sciences, and we remain committed to advancing our solutions to better serve our partners and patients.”
Paysign’s innovative patient affordability platform offers tools that can be configured to the specific needs of each copay assistance program and pharmaceutical manufacturers’ brand strategies. Paysign’s proprietary Dynamic Business Rules enables real-time modifications to program criteria to reduce the impact of copay maximizers, ensuring seamless benefit experiences for patients and providers. Visit paysign.com/rx to learn more about Paysign’s patient affordability offerings.
About Paysign
Paysign, Inc. (NASDAQ: PAYS ) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.
Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107031834/en/
Investor Relations
ir@paysign.com
888.522.4853
paysign.com/investors
Media Relations
Alicia Ches
888.522.4850
pr@paysign.com
FAQ**
How does Paysign Inc. PAYS plan to sustain its growth in patient affordability programs while managing the risks associated with emerging financial threats in the pharmaceutical sector?
With Paysign Inc. PAYS achieving a 200% increase in savings for clients, what specific strategies will the company employ to enhance the capabilities of its Dynamic Business Rules feature in upcoming years?
As Paysign Inc. PAYS assists over 840,000 unique patients, what measures are in place to ensure the continued efficacy of its patient affordability solutions amidst evolving healthcare challenges?
What are Paysign Inc. PAYS's future objectives for expanding its presence within the healthcare ecosystem, especially regarding the integration of fintech and life sciences technologies?
**MWN-AI FAQ is based on asking OpenAI questions about Paysign Inc. (NASDAQ: PAYS).
NASDAQ: PAYS
PAYS Trading
0.41% G/L:
$3.675 Last:
109,930 Volume:
$3.70 Open:
